Search This Blog

Wednesday, September 2, 2026

RenovoRx reaches full enrollment in Phase III TIGeR-PaC pancreatic cancer trial

 


  • Company expects TIGeR-PaC Phase III clinical trial completion in the first half of 2027.
  • Topline data from the TIGeR-PaC pancreatic cancer trial anticipated in the second half of 2027.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)